Gene · 22925
Papers2,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing. | Front Immunol | 2026 | 41743713 | PubTator, text mining | PubMed |
| Anti-PLA2R antibody positivity in adult minimal change disease with tuberculosis co-infection: A case report. | Medicine (Baltimore) | 2026 | 41731792 | PubTator, text mining | PubMed |
| Anti-phospholipase A2 Receptor Membranous Nephropathy Presenting as Common Geriatric Complaints: A Case Report. | Cureus | 2026 | 41728413 | PubTator, text mining | PubMed |
| Response to the Letter to the Editor Entitled "Reconsideration of Response Assessment in Obinutuzumab-Treated Membranous Nephropathy". | Kidney Int Rep | 2026 | 41727779 | PubTator, text mining | PubMed |
| Systemic inflammation and B cell indices predict rituximab responses in membranous nephropathy. | Clin Kidney J | 2026 | 41658280 | PubTator, text mining | PubMed |
| Development of machine learning-driven non-invasive diagnostic models for idiopathic membranous nephropathy in Chinese patients. | Clin Chim Acta | 2026 | 41638545 | PubTator, text mining | PubMed |
| Extracellular Vesicle-Based Urinary Proteomic Signatures Predict Remission and Relapse in Primary Membranous Nephropathy. | Kidney Dis (Basel) | 2026 | 41635560 | PubTator, text mining | PubMed |
| Always Consider a Repeat Kidney Biopsy: Acute Interstitial Nephritis Soon After Membranous Nephropathy. | Case Rep Nephrol | 2026 | 41630985 | PubTator, text mining | PubMed |
| Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy. | Kidney Int Rep | 2026 | 41624448 | PubTator, text mining | PubMed |
| Next-generation Bruton's tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report. | Ann Hematol | 2026 | 41612086 | PubTator, text mining | PubMed |
| Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn's Disease Patients: A Rare-Variant Analysis. | Biomedicines | 2026 | 41595737 | PubTator, text mining | PubMed |
| Significance of glomerular IgG3 deposition in patients with primary membranous nephropathy. | Autoimmunity | 2026 | 41589682 | PubTator, text mining | PubMed |
| CTLA-4 haploinsufficiency presenting with chronic myeloid leukemia, bullous pemphigoid, and PLA2R-positive membranous nephropathy: a case report. | Allergy Asthma Clin Immunol | 2026 | 41582224 | PubTator, text mining | PubMed |
| Long-term real-world outcomes of rituximab in primary membranous nephropathy: a 154-patient cohort study from China. | Ren Fail | 2026 | 41582001 | PubTator, text mining | PubMed |
| Retrospective comparative study on clinical remission rate and safety of rituximab combined with glucocorticoids versus cyclophosphamide monotherapy in patients with membranous nephropathy. | Medicine (Baltimore) | 2026 | 41578483 | PubTator, text mining | PubMed |
| The PLA2R Paradox: Seropositive Membranous Nephropathy With Negative Staining. | Kidney Int Rep | 2026 | 41568269 | PubTator, text mining | PubMed |
| Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. | Antib Ther | 2026 | 41561192 | PubTator, text mining | PubMed |
| Analysis of the clinical significance of serum anti-PLA2R antibodies in evaluating clinical features and therapeutic efficacy in idiopathic membranous nephropathy. | Lab Med | 2026 | 41556301 | PubTator, text mining | PubMed |
| Dual MPO-ANCA and PLA2R positivity in crescentic glomerulonephritis with MPO-associated membranous nephropathy: a case report with pathogenic insights. | CEN Case Rep | 2026 | 41553430 | PubTator, text mining | PubMed |
| Identification of cell senescence-related genes in spontaneous preterm birth based on bioinformatics analysis and machine learning. | PLoS One | 2026 | 41544137 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22925/papers?page=6